Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments
Funding:
Angitia Biopharmaceuticals has secured $120 million in Series C funding led by Bain Capital Life Sciences, with participation from new and existing investors23.
Purpose:
The funding will support the development of Angitia's pipeline of novel treatments for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta (OI), and spinal fusion23.
Product Candidates: The company is advancing three biologic product candidates:
AGA2118:
A bispecific antibody targeting sclerostin and DKK1 for the treatment of osteoporosis, currently in a Phase 2 study2.
AGA2115:
A bispecific antibody targeting sclerostin and DKK1 for the treatment of osteogenesis imperfecta (OI), currently in a first-in-human study2.
AGA111:
A biologic to promote spinal fusion in patients with degenerative disc disease, currently in a Phase 3 study2.
Leadership:
Dr. Norbert Riedel, Ph.D., will join Angitia's Board of Directors, bringing extensive leadership experience in the biopharmaceutical industry2.
Company Overview:
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapeutics for serious musculoskeletal diseases24.
Sources:
2. https://www.biospace.com/press-releases/angitia-biopharmaceuticals-announces-120-million-series-c-financing